scholarly journals Hubungan Status Frailty dengan Serokonversi dan Seroproteksi Vaksin Influenza pada Populasi Usia Lanjut

2017 ◽  
Vol 3 (4) ◽  
pp. 212
Author(s):  
Sukamto Koesnoe ◽  
Ummu Habibah ◽  
Edy Rizal Wahyudi ◽  
Murdani Abdullah

Pendahuluan. Infeksi masih merupakan ancaman yang serius bagi dunia kesehatan saat ini, terutama bagi populasi khusus seperti usia lanjut. Usia dinyatakan sebagai salah satu faktor prediktor dalam keberhasilan vaksinasi. Semakin tua usia seseorang, respon imunnya akan semakin buruk. Respon yang berbeda pada usia lanjut ini diperkirakan karena frailty dan kejadian immunosenescense yang mendasarinya. Penelitian ini dilakukan untuk mengetahui hubungan status frailty dengan respon imun pascavaksinasi influenza pada populasi usia lanjut.Metode. Studi kohort retrospektif ini mengambil data dari penelitian induk dengan subjek usia lanjut berusia ≥60 yang tergabung dalam Posyandu Lansia di 4 kelurahan di Kecamatan Pulo Gadung, Jakarta Timur. Status frailty ditentukan berdasarkan kuisoner Frailty Index 40 Items (FI-40). Vaksin Influenza yang dievaluasi adalah vaksin influenza trivalen inaktif. Serokonversi didefinisikan sebagai peningkatan titer inhibisi hemagglutinin sebanyak 4x lipat. Seroproteksi didefinisikan sebagai titer inhibisi hemagglutinin ≥1:40.Hasil. Terdapat 140 subjek penelitian. Tingkat serokonversi vaksin influenza pada kelompok frail, pre-frail dan sehat adalah 37,9%, 39% dan 60%. Tingkat seroproteksi vaksin influenza pada kelompok frail, pre-frail dan sehat adalah 80%, 92,2% dan 94,8% . Risiko relatif (RR) kelompok pre-frail/frail untuk kejadian tidak serokonversi adalah 0,93 (IK 95% 0,72-1,02) dan RR untuk kejadian tidak seroproteksi adalah 1,7 ( IK 95% 0,5-6,2).Simpulan. Tidak ditemukan hubungan antara status frailty dengan serokonversi dan seroproteksi vaksin influenza pada populasi usia lanjut.Kata Kunci: Frailty, pre-frail, frail, serokonversi, seroproteksi, usia lanjut, vaksin influenza  Correlation of Frailty Status with Influenza Vaccine Seroconversion and Seroprotection among Elderly PopulationIntroduction. Infection is still considered as a serious health threat in the world, especially among the elderly. Age was identified as one of the predictor factors for successfull vaccination. Immune response would decrease in older people. A different response in the elderly is expected from frailty and underlying immunosenescense events. This study was conducted to determine the relationship with the Frailty status after the vaccination immune response of influenza in the elderly population. Methods. This retrospective cohort study was conducted using secondary data from the parent study of elderly subjects age ≥60 years who live in the community of Posyandu lansia in Pulo Gadung Region, East Jakarta. Frailty status was stated by Frailty Index 40 Items (FI-40). The influenza vaccine evaluated was the Trivalent Inactivated Vaccine. Seroconversion defined as four fold increase hemagglutinin inhibition titre. Seroprotection defined as Hemagglutinin Inhibition titer ≥1:40. Results. There are 140 subject included in this study. Seroconversion influenza vaccine rate in frail, pre-frail, and robust group are 37.9%, 39%, 60%, respectively. Seroprotection rate in frail, pre-frail, and robust group are 80%, 92.2%, 94.8%, respectively. Relative Risk (RR) pre-frail/frail group for not seroconverted is 0.93 (CI 95% 0.72-1.02), and RR for not seroprotected is 1,7 ( CI 95% 0.5-6.2). Conclussions. There is no association between frailty status and seroconversion nor seroprotection of influenza vaccine in elderly population. Keywords: elderly, frail, influenza vaccine, pre-frail, seroconversion, seroprotection

Vaccine ◽  
2014 ◽  
Vol 32 (44) ◽  
pp. 5816-5823 ◽  
Author(s):  
Jacob Atsmon ◽  
Yoseph Caraco ◽  
Sagit Ziv-Sefer ◽  
Dimitry Shaikevich ◽  
Ester Abramov ◽  
...  

Vaccine ◽  
2019 ◽  
Vol 37 (36) ◽  
pp. 5314-5322 ◽  
Author(s):  
Massimo Fabiani ◽  
Enrico Volpe ◽  
Maurizio Faraone ◽  
Antonino Bella ◽  
Caterina Rizzo ◽  
...  

2020 ◽  
Vol 19 (5) ◽  
pp. 479-489
Author(s):  
Massimo Fabiani ◽  
Enrico Volpe ◽  
Maurizio Faraone ◽  
Antonino Bella ◽  
Patrizio Pezzotti ◽  
...  

2012 ◽  
Vol 19 (12) ◽  
pp. 1943-1948 ◽  
Author(s):  
Iván Bihari ◽  
Gyula Pánczél ◽  
Jozsef Kovacs ◽  
Jenny Beygo ◽  
Elena Fragapane

ABSTRACTPreparedness against an A/H5N1 influenza pandemic requires well-tolerated, effective vaccines which provide both vaccine strain-specific and heterologous, cross-clade protection. This study was conducted to assess the immunogenicity and safety profile of an MF59-adjuvanted, prepandemic influenza vaccine containing A/turkey/Turkey/01/2005 (H5N1) strain viral antigen. A total of 343 participants, 194 adults (18 to 60 years) and 149 elderly individuals (≥61 years), received two doses of the investigational vaccine given 3 weeks apart. Homologous and heterologous antibody responses were analyzed by hemagglutination inhibition (HI), single radial hemolysis (SRH), and microneutralization (MN) assays 3 weeks after administration of the first vaccine dose and 3 weeks and 6 months after the second dose. Immunogenicity was assessed according to European licensure criteria for pandemic influenza vaccines. After two vaccine doses, all three European licensure criteria were met for adult and elderly subjects against the homologous vaccine strain, A/turkey/Turkey/1/2005, when analyzed by HI and SRH assays. Cross-reactive antibody responses were observed by HI and SRH analyses against the heterologous H5N1 strains, A/Indonesia/5/2005 and A/Vietnam/1194/2004, in adult and elderly subjects. Solicited local and systemic reactions were mostly mild to moderate in severity and occurred less frequently in the elderly than in adult vaccinees. In both adult and elderly subjects, MF59-adjuvanted vaccine containing 7.5 μg of A/Turkey strain influenza virus antigen was highly immunogenic, well tolerated, and able to elicit cross-clade, heterologous antibody responses against A/Indonesia and A/Vietnam strains 6 weeks after the first vaccination.


Sign in / Sign up

Export Citation Format

Share Document